Does the media favor VKTX or MDGL?

In the previous week, Viking Therapeutics had 8 more articles in the media than Madrigal Pharmaceuticals. MarketBeat recorded 12 mentions for Viking Therapeutics and 4 mentions for Madrigal Pharmaceuticals. Madrigal Pharmaceuticals' average media sentiment score of 0.91 beat Viking Therapeutics' score of 0.67 indicating that Madrigal Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Viking Therapeutics 4 Very Positive mention(s) 2 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Madrigal Pharmaceuticals 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer LLY or VKTX?

In the previous week, Eli Lilly and Company had 126 more articles in the media than Viking Therapeutics. MarketBeat recorded 138 mentions for Eli Lilly and Company and 12 mentions for Viking Therapeutics. Eli Lilly and Company's average media sentiment score of 1.03 beat Viking Therapeutics' score of 0.67 indicating that Eli Lilly and Company is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Eli Lilly and Company 89 Very Positive mention(s) 15 Positive mention(s) 24 Neutral mention(s) 3 Negative mention(s) 4 Very Negative mention(s) Positive Viking Therapeutics 4 Very Positive mention(s) 2 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor VKTX or PFE?

In the previous week, Pfizer had 54 more articles in the media than Viking Therapeutics. MarketBeat recorded 66 mentions for Pfizer and 12 mentions for Viking Therapeutics. Viking Therapeutics' average media sentiment score of 0.67 beat Pfizer's score of 0.40 indicating that Viking Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Viking Therapeutics 4 Very Positive mention(s) 2 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Pfizer 25 Very Positive mention(s) 10 Positive mention(s) 10 Neutral mention(s) 11 Negative mention(s) 7 Very Negative mention(s) Neutral

Does the media prefer GMAB or VKTX?

In the previous week, Viking Therapeutics had 7 more articles in the media than Genmab A/S. MarketBeat recorded 12 mentions for Viking Therapeutics and 5 mentions for Genmab A/S. Genmab A/S's average media sentiment score of 1.11 beat Viking Therapeutics' score of 0.67 indicating that Genmab A/S is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Genmab A/S 2 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Viking Therapeutics 4 Very Positive mention(s) 2 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer ASND or VKTX?

In the previous week, Viking Therapeutics had 8 more articles in the media than Ascendis Pharma A/S. MarketBeat recorded 12 mentions for Viking Therapeutics and 4 mentions for Ascendis Pharma A/S. Viking Therapeutics' average media sentiment score of 0.67 beat Ascendis Pharma A/S's score of 0.25 indicating that Viking Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ascendis Pharma A/S 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Viking Therapeutics 4 Very Positive mention(s) 2 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Viking Therapeutics (VKTX) Competitors

$38.86 -2.28 (-5.54%)

Closing price 07/10/2026 04:00 PM Eastern

Extended Trading

$38.82 -0.04 (-0.11%)

As of 07/10/2026 07:57 PM Eastern

Compare

VKTX vs. MDGL, LLY, PFE, GMAB, and ASND

Should you buy Viking Therapeutics stock or one of its competitors? MarketBeat compares Viking Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Viking Therapeutics include Madrigal Pharmaceuticals (MDGL), Eli Lilly and Company (LLY), Pfizer (PFE), Genmab A/S (GMAB), and Ascendis Pharma A/S (ASND). These companies are all part of the "medical" sector.

How does Viking Therapeutics compare to Madrigal Pharmaceuticals?

Viking Therapeutics (NASDAQ:VKTX) and Madrigal Pharmaceuticals (NASDAQ:MDGL) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their profitability, risk, dividends, valuation, media sentiment, analyst recommendations, earnings and institutional ownership.

Viking Therapeutics presently has a consensus price target of $93.60, suggesting a potential upside of 140.86%. Madrigal Pharmaceuticals has a consensus price target of $687.93, suggesting a potential upside of 28.18%. Given Viking Therapeutics' stronger consensus rating and higher probable upside, equities analysts plainly believe Viking Therapeutics is more favorable than Madrigal Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Viking Therapeutics	1 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	2 Strong Buy rating(s)	2.79
Madrigal Pharmaceuticals	1 Sell rating(s)	3 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.78

Viking Therapeutics has a beta of 0.66, indicating that its share price is 34% less volatile than the broader market. Comparatively, Madrigal Pharmaceuticals has a beta of -1.05, indicating that its share price is 205% less volatile than the broader market.

In the previous week, Viking Therapeutics had 8 more articles in the media than Madrigal Pharmaceuticals. MarketBeat recorded 12 mentions for Viking Therapeutics and 4 mentions for Madrigal Pharmaceuticals. Madrigal Pharmaceuticals' average media sentiment score of 0.91 beat Viking Therapeutics' score of 0.67 indicating that Madrigal Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Viking Therapeutics	4 Very Positive mention(s)	2 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Madrigal Pharmaceuticals	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Viking Therapeutics has a net margin of 0.00% compared to Madrigal Pharmaceuticals' net margin of -27.32%. Madrigal Pharmaceuticals' return on equity of -50.15% beat Viking Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Viking Therapeutics	N/A	-71.31%	-65.35%
Madrigal Pharmaceuticals	-27.32%	-50.15%	-25.44%

76.0% of Viking Therapeutics shares are held by institutional investors. Comparatively, 98.5% of Madrigal Pharmaceuticals shares are held by institutional investors. 5.3% of Viking Therapeutics shares are held by insiders. Comparatively, 17.6% of Madrigal Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Madrigal Pharmaceuticals has higher revenue and earnings than Viking Therapeutics. Madrigal Pharmaceuticals is trading at a lower price-to-earnings ratio than Viking Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Viking Therapeutics	N/A	N/A	-$359.64M	-$4.14	N/A
Madrigal Pharmaceuticals	$958.40M	12.91	-$288.28M	-$12.80	N/A

Summary

Viking Therapeutics and Madrigal Pharmaceuticals tied by winning 8 of the 16 factors compared between the two stocks.

How does Viking Therapeutics compare to Eli Lilly and Company?

Eli Lilly and Company (NYSE:LLY) and Viking Therapeutics (NASDAQ:VKTX) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, institutional ownership, valuation, analyst recommendations, media sentiment, risk, earnings and profitability.

Eli Lilly and Company presently has a consensus target price of $1,263.41, suggesting a potential upside of 6.25%. Viking Therapeutics has a consensus target price of $93.60, suggesting a potential upside of 140.86%. Given Viking Therapeutics' higher probable upside, analysts clearly believe Viking Therapeutics is more favorable than Eli Lilly and Company.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Eli Lilly and Company	1 Sell rating(s)	4 Hold rating(s)	23 Buy rating(s)	2 Strong Buy rating(s)	2.87
Viking Therapeutics	1 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	2 Strong Buy rating(s)	2.79

82.5% of Eli Lilly and Company shares are owned by institutional investors. Comparatively, 76.0% of Viking Therapeutics shares are owned by institutional investors. 0.1% of Eli Lilly and Company shares are owned by insiders. Comparatively, 5.3% of Viking Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Eli Lilly and Company had 126 more articles in the media than Viking Therapeutics. MarketBeat recorded 138 mentions for Eli Lilly and Company and 12 mentions for Viking Therapeutics. Eli Lilly and Company's average media sentiment score of 1.03 beat Viking Therapeutics' score of 0.67 indicating that Eli Lilly and Company is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Eli Lilly and Company	89 Very Positive mention(s)	15 Positive mention(s)	24 Neutral mention(s)	3 Negative mention(s)	4 Very Negative mention(s)	Positive
Viking Therapeutics	4 Very Positive mention(s)	2 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Eli Lilly and Company has a beta of 0.51, meaning that its stock price is 49% less volatile than the broader market. Comparatively, Viking Therapeutics has a beta of 0.66, meaning that its stock price is 34% less volatile than the broader market.

Eli Lilly and Company has higher revenue and earnings than Viking Therapeutics. Viking Therapeutics is trading at a lower price-to-earnings ratio than Eli Lilly and Company, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Eli Lilly and Company	$65.18B	17.18	$20.64B	$28.15	42.24
Viking Therapeutics	N/A	N/A	-$359.64M	-$4.14	N/A

Eli Lilly and Company has a net margin of 34.98% compared to Viking Therapeutics' net margin of 0.00%. Eli Lilly and Company's return on equity of 105.77% beat Viking Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Eli Lilly and Company	34.98%	105.77%	23.76%
Viking Therapeutics	N/A	-71.31%	-65.35%

Summary

Eli Lilly and Company beats Viking Therapeutics on 12 of the 15 factors compared between the two stocks.

How does Viking Therapeutics compare to Pfizer?

Viking Therapeutics (NASDAQ:VKTX) and Pfizer (NYSE:PFE) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, valuation, earnings, dividends, institutional ownership, media sentiment, risk and profitability.

Pfizer has higher revenue and earnings than Viking Therapeutics. Viking Therapeutics is trading at a lower price-to-earnings ratio than Pfizer, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Viking Therapeutics	N/A	N/A	-$359.64M	-$4.14	N/A
Pfizer	$62.58B	2.21	$7.77B	$1.31	18.48

Viking Therapeutics presently has a consensus price target of $93.60, indicating a potential upside of 140.86%. Pfizer has a consensus price target of $28.56, indicating a potential upside of 17.93%. Given Viking Therapeutics' stronger consensus rating and higher possible upside, research analysts clearly believe Viking Therapeutics is more favorable than Pfizer.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Viking Therapeutics	1 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	2 Strong Buy rating(s)	2.79
Pfizer	2 Sell rating(s)	14 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.19

In the previous week, Pfizer had 54 more articles in the media than Viking Therapeutics. MarketBeat recorded 66 mentions for Pfizer and 12 mentions for Viking Therapeutics. Viking Therapeutics' average media sentiment score of 0.67 beat Pfizer's score of 0.40 indicating that Viking Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Viking Therapeutics	4 Very Positive mention(s)	2 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Pfizer	25 Very Positive mention(s)	10 Positive mention(s)	10 Neutral mention(s)	11 Negative mention(s)	7 Very Negative mention(s)	Neutral

Viking Therapeutics has a beta of 0.66, meaning that its share price is 34% less volatile than the broader market. Comparatively, Pfizer has a beta of 0.35, meaning that its share price is 65% less volatile than the broader market.

Pfizer has a net margin of 11.83% compared to Viking Therapeutics' net margin of 0.00%. Pfizer's return on equity of 19.44% beat Viking Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Viking Therapeutics	N/A	-71.31%	-65.35%
Pfizer	11.83%	19.44%	8.41%

76.0% of Viking Therapeutics shares are owned by institutional investors. Comparatively, 68.4% of Pfizer shares are owned by institutional investors. 5.3% of Viking Therapeutics shares are owned by insiders. Comparatively, 0.6% of Pfizer shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

Viking Therapeutics and Pfizer tied by winning 8 of the 16 factors compared between the two stocks.

How does Viking Therapeutics compare to Genmab A/S?

Genmab A/S (NASDAQ:GMAB) and Viking Therapeutics (NASDAQ:VKTX) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, earnings, media sentiment, profitability, analyst recommendations, institutional ownership, valuation and dividends.

Genmab A/S has a net margin of 21.05% compared to Viking Therapeutics' net margin of 0.00%. Genmab A/S's return on equity of 15.34% beat Viking Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Genmab A/S	21.05%	15.34%	8.94%
Viking Therapeutics	N/A	-71.31%	-65.35%

Genmab A/S has higher revenue and earnings than Viking Therapeutics. Viking Therapeutics is trading at a lower price-to-earnings ratio than Genmab A/S, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Genmab A/S	$3.72B	4.86	$963M	$1.32	21.97
Viking Therapeutics	N/A	N/A	-$359.64M	-$4.14	N/A

Genmab A/S has a beta of 0.84, indicating that its share price is 16% less volatile than the broader market. Comparatively, Viking Therapeutics has a beta of 0.66, indicating that its share price is 34% less volatile than the broader market.

Genmab A/S presently has a consensus target price of $38.21, indicating a potential upside of 31.77%. Viking Therapeutics has a consensus target price of $93.60, indicating a potential upside of 140.86%. Given Viking Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Viking Therapeutics is more favorable than Genmab A/S.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Genmab A/S	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.75
Viking Therapeutics	1 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	2 Strong Buy rating(s)	2.79

In the previous week, Viking Therapeutics had 7 more articles in the media than Genmab A/S. MarketBeat recorded 12 mentions for Viking Therapeutics and 5 mentions for Genmab A/S. Genmab A/S's average media sentiment score of 1.11 beat Viking Therapeutics' score of 0.67 indicating that Genmab A/S is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Genmab A/S	2 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Viking Therapeutics	4 Very Positive mention(s)	2 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

7.1% of Genmab A/S shares are owned by institutional investors. Comparatively, 76.0% of Viking Therapeutics shares are owned by institutional investors. 1.5% of Genmab A/S shares are owned by insiders. Comparatively, 5.3% of Viking Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Summary

Genmab A/S beats Viking Therapeutics on 9 of the 15 factors compared between the two stocks.

How does Viking Therapeutics compare to Ascendis Pharma A/S?

Ascendis Pharma A/S (NASDAQ:ASND) and Viking Therapeutics (NASDAQ:VKTX) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their media sentiment, analyst recommendations, institutional ownership, earnings, valuation, profitability, risk and dividends.

Ascendis Pharma A/S has a net margin of 57.87% compared to Viking Therapeutics' net margin of 0.00%. Ascendis Pharma A/S's return on equity of 0.00% beat Viking Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ascendis Pharma A/S	57.87%	N/A	-8.37%
Viking Therapeutics	N/A	-71.31%	-65.35%

76.0% of Viking Therapeutics shares are held by institutional investors. 40.0% of Ascendis Pharma A/S shares are held by company insiders. Comparatively, 5.3% of Viking Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Ascendis Pharma A/S has higher revenue and earnings than Viking Therapeutics. Viking Therapeutics is trading at a lower price-to-earnings ratio than Ascendis Pharma A/S, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ascendis Pharma A/S	$814.57M	20.71	-$258M	$8.67	31.19
Viking Therapeutics	N/A	N/A	-$359.64M	-$4.14	N/A

Ascendis Pharma A/S has a beta of 0.37, suggesting that its stock price is 63% less volatile than the broader market. Comparatively, Viking Therapeutics has a beta of 0.66, suggesting that its stock price is 34% less volatile than the broader market.

In the previous week, Viking Therapeutics had 8 more articles in the media than Ascendis Pharma A/S. MarketBeat recorded 12 mentions for Viking Therapeutics and 4 mentions for Ascendis Pharma A/S. Viking Therapeutics' average media sentiment score of 0.67 beat Ascendis Pharma A/S's score of 0.25 indicating that Viking Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ascendis Pharma A/S	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Viking Therapeutics	4 Very Positive mention(s)	2 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Ascendis Pharma A/S presently has a consensus price target of $295.67, suggesting a potential upside of 9.32%. Viking Therapeutics has a consensus price target of $93.60, suggesting a potential upside of 140.86%. Given Viking Therapeutics' higher probable upside, analysts clearly believe Viking Therapeutics is more favorable than Ascendis Pharma A/S.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ascendis Pharma A/S	1 Sell rating(s)	0 Hold rating(s)	16 Buy rating(s)	2 Strong Buy rating(s)	3.00
Viking Therapeutics	1 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	2 Strong Buy rating(s)	2.79

Summary

Ascendis Pharma A/S beats Viking Therapeutics on 10 of the 15 factors compared between the two stocks.

Get Viking Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding VKTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

VKTX vs. The Competition

Export

Metric	Viking Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$4.78B	$3.79B	$7.12B	$12.61B
Dividend Yield	N/A	2.17%	2.68%	7.83%
P/E Ratio	-9.39	21.27	27.22	24.56
Price / Sales	N/A	323.90	590.16	121.71
Price / Cash	N/A	147.64	49.34	60.04
Price / Book	6.88	8.41	10.90	6.39
Net Income	-$359.64M	$23.85M	$3.57B	$331.44M
7 Day Performance	3.79%	-0.76%	-0.25%	0.37%
1 Month Performance	35.83%	11.35%	5.77%	2.17%
1 Year Performance	24.91%	51.68%	28.14%	20.90%

Viking Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
VKTX Viking Therapeutics	3.343 of 5 stars	$38.86 -5.5%	$93.60 +140.9%	+24.2%	$4.78B	N/A	N/A	20	News Coverage
MDGL Madrigal Pharmaceuticals	4.1615 of 5 stars	$514.39 -4.2%	$687.93 +33.7%	+70.6%	$12.38B	$958.40M	N/A	90
LLY Eli Lilly and Company	4.6733 of 5 stars	$1,192.16 -0.6%	$1,235.07 +3.6%	+50.5%	$1.13T	$65.18B	42.35	50,000	Trending News Analyst Forecast
PFE Pfizer	4.2822 of 5 stars	$23.88 -0.9%	$28.82 +20.7%	-6.0%	$137.24B	$62.58B	18.23	75,000	Trending News Analyst Forecast
GMAB Genmab A/S	4.6804 of 5 stars	$27.64 +0.6%	$37.93 +37.2%	+32.7%	$17.13B	$3.72B	20.94	3,029	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:VKTX) was last updated on 7/11/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Viking Therapeutics (VKTX) Competitors

VKTX vs. MDGL, LLY, PFE, GMAB, and ASND

How does Viking Therapeutics compare to Madrigal Pharmaceuticals?

Summary

How does Viking Therapeutics compare to Eli Lilly and Company?

Summary

How does Viking Therapeutics compare to Pfizer?

Summary

How does Viking Therapeutics compare to Genmab A/S?

Summary

How does Viking Therapeutics compare to Ascendis Pharma A/S?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VKTX vs. The Competition

Viking Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Viking Therapeutics (VKTX) Competitors

VKTX vs. MDGL, LLY, PFE, GMAB, and ASND

How does Viking Therapeutics compare to Madrigal Pharmaceuticals?

Do analysts recommend VKTX or MDGL?

Which has more risk and volatility, VKTX or MDGL?

Does the media favor VKTX or MDGL?

Is VKTX or MDGL more profitable?

Do insiders and institutionals hold more shares of VKTX or MDGL?

Which has stronger valuation & earnings, VKTX or MDGL?

Summary

How does Viking Therapeutics compare to Eli Lilly and Company?

Do analysts prefer LLY or VKTX?

Do insiders & institutionals have more ownership in LLY or VKTX?

Does the media prefer LLY or VKTX?

Which has more volatility and risk, LLY or VKTX?

Which has preferable valuation & earnings, LLY or VKTX?

Is LLY or VKTX more profitable?

Summary

How does Viking Therapeutics compare to Pfizer?

Which has preferable valuation & earnings, VKTX or PFE?

Do analysts recommend VKTX or PFE?

Does the media favor VKTX or PFE?

Which has more volatility & risk, VKTX or PFE?

Is VKTX or PFE more profitable?

Do insiders & institutionals believe in VKTX or PFE?

Summary

How does Viking Therapeutics compare to Genmab A/S?

Is GMAB or VKTX more profitable?

Which has higher valuation & earnings, GMAB or VKTX?

Which has more risk and volatility, GMAB or VKTX?

Do analysts recommend GMAB or VKTX?

Does the media prefer GMAB or VKTX?

Do insiders and institutionals believe in GMAB or VKTX?

Summary

How does Viking Therapeutics compare to Ascendis Pharma A/S?

Is ASND or VKTX more profitable?

Do insiders and institutionals have more ownership in ASND or VKTX?

Which has better earnings and valuation, ASND or VKTX?

Which has more risk and volatility, ASND or VKTX?

Does the media prefer ASND or VKTX?

Do analysts recommend ASND or VKTX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VKTX vs. The Competition

Viking Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools